Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Taxi cab key chain
Belt with light
Print system
Press nut
Blended block copolymer composition
Mobile tablet information handling system support
Rear body panel cover for a motor vehicle
  Randomly Featured Patents
Catch basin grate riser
Arrangement for transport and/or safekeeping of a human or animal tissue sample
Endostatin protein and fragments thereof
Fluidic piezoresistive strain gauge
Ceramic package for memory semiconductor
Screw actuator with a fixed nut
Floating dry dock
Flexible joint methodology to attach a die on an organic substrate
Sanitary swab collection system, microfluidic assay device, and methods for diagnostic assays
Flywheel configuration for a power tool